CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.
Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Medicare to cover more brain scans for Alzheimer’s patients
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures
